Archive | News

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

MAXCYTE-New-Logo-2016-LARGE

CAMBRIDGE, Mass., and GAITHERSBURG, Md., – October 7, 2019:– Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell […]

Comments Off on Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines Continue Reading →

KaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland Faculty

Kalocyte

Biotechnology Company Is Developing Synthetic Blood Product for Use in Trauma Settings BALTIMORE, Sept. 23, 2019 /PRNewswire/ — KaloCyte, a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has joined Baltimore’s growing biotech community as a University of Maryland […]

Comments Off on KaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland Faculty Continue Reading →

BioBuzz: GlycoMimetics CEO Rachel King Among Female Execs Setting Standard of Excellence in Biohealth Capital Region

RachelKing

Liftstream, a U.K.-based executive recruiting firm, released an oft referenced report called “A Public Reality for Women in Biotech Boardrooms” in 2016. Lifstream’s research found that only 7 to 9 percent of biotech CEOs were women, less than 11 percent of board seats were held by females and 98 percent of board chair positions were held by […]

Comments Off on BioBuzz: GlycoMimetics CEO Rachel King Among Female Execs Setting Standard of Excellence in Biohealth Capital Region Continue Reading →

GlycoMimetics CEO Rachel King Featured in Article on Uproleselan

RachelKing

In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]

Comments Off on GlycoMimetics CEO Rachel King Featured in Article on Uproleselan Continue Reading →

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

MAXCYTE-New-Logo-2016-LARGE

–      No dose-limiting toxicities or safety concerns observed in first cohort of treated patients–      Feasibility of streamlined, faster CAR therapy manufacturing process confirmed–      Dosing initiated in second cohort of patients Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it […]

Comments Off on MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform Continue Reading →

UMB startup CoapTech receives FDA clearance for feeding tube placement device

coaptech logo

The company’s device uses ultrasound, which will allow a feeding tube to be placed without need for a surgical setting. With regulatory approval, it’s taking a key step toward commercialization. Baltimore-based medical device startup CoapTech reached a key milestone in April: It can now market its product that allows the placement of a feeding tube without the […]

Comments Off on UMB startup CoapTech receives FDA clearance for feeding tube placement device Continue Reading →

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

MAXCYTE-New-Logo-2016-LARGE

– CARMA drug candidates can be manufactured via streamlined, single-day process, providing a much needed faster turnaround of autologous cell therapy to patients– CARMA cell therapies are engineered with the intention of reducing potential adverse events that have been evident with other CAR technologies and to allow for multiple dosing, an important feature for potential […]

Comments Off on MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing Continue Reading →

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

3V

30 APRIL 2019 San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) […]

Comments Off on 3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH Continue Reading →

GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]

Comments Off on GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Continue Reading →

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

logo-glyco

Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]

Comments Off on GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Continue Reading →